Vireo Growth (VREOF) Gains from Investment Securities (2024 - 2026)
Vireo Growth (VREOF) reported Gains from Investment Securities of $5.5 million for Q1 2026, up 1000.0% on a YoY basis from $500000.0 in Q1 2025, and up 1664.33% sequentially from -$351588.0 in Q4 2025.
Vireo Growth (VREOF) Gains from Investment Securities (2024 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 3 years of Gains from Investment Securities data on file, last reported at $5.5 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 1000.0% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.6 million (up 273.85% YoY), and the FY2025 full-year result was $586273.0, up 275.73% from the prior year.
- Gains from Investment Securities grew to $5.5 million in Q1 2026, from -$351588.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $5.5 million in Q1 2026 to a low of -$1.6 million in Q2 2024.
- A 3-year average of $639184.6 and a median of -$60663.0 in 2025 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities plunged 111.91% in 2025 and jumped 1000.0% in 2026, its largest moves.
- Tracing VREOF's Gains from Investment Securities over 3 years: stood at $3.0 million in 2024, then plunged by 111.91% to -$351588.0 in 2025, then soared by 1664.33% to $5.5 million in 2026.
- Business Quant data shows VREOF's Gains from Investment Securities at $5.5 million in Q1 2026, -$351588.0 in Q4 2025, and -$60663.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.82 Bn | 87.96 Bn | - |
| 2 | Teva Pharmaceutical Industries | 36.03 Bn | 32.29 Bn | 1.97 Bn |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.50 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.02 Bn | 20.86 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.43 Bn | 18.63 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.73 Bn | 12.30 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.50 Mn |
| Mar 31, 2026 | 5.50 Mn |
| Dec 31, 2025 | -351,588.00 |
| Dec 31, 2025 | -351,588.00 |
| Sep 30, 2025 | -60,663.00 |
| Sep 30, 2025 | -60,663.00 |
| Jun 30, 2025 | 498,524.00 |
| Jun 30, 2025 | 498,524.00 |
| Mar 31, 2025 | 500,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 2.95 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Sep 30, 2024 | -354,328.00 |
| Sep 30, 2024 | -354,328.00 |
| Jun 30, 2024 | -1.60 Mn |
| Jun 30, 2024 | -1.60 Mn |
| Mar 31, 2024 | -1.33 Mn |
| Mar 31, 2024 | -1.33 Mn |